Minister Jeong Eun-kyeong Inspects Progress of Therapy at Yeouido St. Mary's Hospital

Autologous EBV-Specific T Cells Administered Eight Times Over 12 Weeks...Treatment Cost Set at 76 Million Won

The first advanced regenerative medicine therapy approved in Korea has now begun to be administered to actual patients.


First Advanced Regenerative Medicine Therapy Begins in Korea for High-Risk Rare Hematologic Cancer Patients View original image

The Ministry of Health and Welfare announced that on September 22, Minister Jeong Eun-kyeong visited The Catholic University of Korea Yeouido St. Mary's Hospital, where the first advanced regenerative medicine therapy was performed. She inspected the treatment preparations and progress, and interviewed the first registered patient.


This therapy marks the first approved case in Korea since the advanced regenerative medicine treatment system was introduced in February of last year. The treatment involves administration of the autologous immune cell therapy VT-EBV-N to patients in complete remission of EBV-positive, extranodal NK/T-cell lymphoma who are at high risk of relapse, aiming to prevent recurrence and promote long-term survival.


The target patients are those with EBV-positive, extranodal NK/T-cell lymphoma who, although currently in complete remission with no detectable cancer after chemotherapy, still face a high risk of relapse. The treatment uses EBV antigen-specific immune cells derived from the patient to prevent cancer recurrence.


The therapy is conducted by intravenous administration of autologous EBV-specific T cells. It is given once per week for four weeks, followed by a four-week break, and then once per week for another four weeks. The entire course consists of eight administrations over 12 weeks. A total of 15 patients will undergo the treatment.


The treatment costs 76,207,178 won. Patients pay 40 million won at the time of treatment, and an additional 30 million won if there is no recurrence within five years after treatment. If relapse occurs within five years, the entire amount is refunded.


On this day, the Ministry of Health and Welfare inspected the hospital's safety management system, overall treatment preparations, and the process leading up to the first therapy. The site visit included tours of relevant facilities. The Minister also met with the first registered patient to hear feedback and any difficulties faced. The visit included time to meet with the research and medical teams involved in developing the therapy and to express gratitude and words of encouragement for their efforts.



Minister Jeong stated, "Advanced regenerative medicine treatment will offer new therapeutic options to patients suffering from serious, rare, and intractable diseases," adding, "While ensuring safety, we will continue to improve related systems and provide support to enhance patient access to these treatments."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing